2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester4-isobutoxyisophthalonitrile3-cyanoisobutoxybenzothioamide4-nitrobenzonitrilemethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylateiso-butyl ester of febuxostat
合成工艺路线路线简述
4-羟基硫代苯甲酰胺置于盐酸羟胺,水,Potassium Carbonate,三乙胺,Sodium Hydroxide,Magnesium Chloride体系中,用 四氢呋喃,甲醇,N,N-二甲基甲酰胺,乙腈 用作溶剂,化学反应 1.17H,反应生成非布索坦 参考文献:Synthesis,Molecular Docking,Dft Study Of Novel N-Benzyl-2-(3-Cyano-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxamide Derivatives And Their Antibacterial Activity 标题:Synthesis,Molecular Docking,Dft Study Of Novel N-Benzyl-2-(3-Cyano-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxamide Derivatives And Their Antibacterial Activity 摘要:使用微波方法合成了一系列基于非布索他的新化学实体,并通过核磁共振,质谱和傅里叶变换红外光谱研究进行了表征.非布索他酰胺核取代化合物8C(-7.91Kcal/mol),8G(-7.94 Kcal/mol)的分子对接显示出高结合能对抗alk受体.通过b3Lyp/6-31G方法计算了meps,Homo,Lumo和homo-Lumo能隙的理论研究.在测试的化合物中,甲氧基取代化合物8G对金黄色葡萄球菌和枯草杆菌显示出最高的抗菌活性. Doi:10.14233/ajchem.2020.22390
专利号:US-2021107859-A1 优先权日:2018-04-06 标题 :A process for the synthesis of carbon labeled organic compounds 发明人:AUDISIO DAVIDE; CANTAT THIBAULT; DESTRO GIANLUCA 权利人:COMMISSARIAT ENERGIE ATOMIQUE 摘要:A process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group is described. A method of using carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; a process for manufacturing labeled pharmaceuticals and agrochemicals comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure; and a process for producing tracers comprising synthesis of carbon labeled organic compounds containing a carbon labeled carboxyl group according to the present disclosure are also described.
专利号:US-2025206743-A1 优先权日:2022-03-25 标 题:Tyk2 inhibitor synthesis and intermediates thereof 发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG 权利人:TAKEDA PHARMACEUTICALS CO 摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
专利号:US-2016194279-A1 优先权日:2012-12-09 标 题 :One pot process for the conversion of aroyl chlorides to acyl thioureas 发明人:CHEPURI VENKATA RAMANA; BEERAN SENTHILKUMAR 权利人:COUNCIL SCIENT IND RES 摘要:The present invention disclose an improved one pot process for synthesis of acyl thioureas of formula (I), with yield greater than 80%, from aroyl chlorides of formula (I) wherein, R′ is an aryl or a heteroarylene group substituted with one or more groups selected from hydrogen, alkyl, alkylene, alkynyl, alkoxy, alkenyloxy, halo, hydroxyl, nitro, amino, carboxyl, ester, halogenated hydrocarbon or an aryl or heteroaryl; R″ and R′″ are selected independently from hydrogen, alkyl, alkylene, alkynyl, alkoxy, alkenyloxy, halo, hydroxyl, nitro, amino or halogenated hydrocarbon.
专利号:US-10906888-B2 优先权日:2016-07-14 标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme 发明人:CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE 权利人:PFIZER 摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-2024239768-A1 优先权日:2021-04-27 标题 :Method for preparing xanthine oxidase inhibitor 发明人:RYU IN AE; LEE JU YOUNG; YOON JOO YONG; LEE SEOK JU; PARK AH BYEOL; KIM KI DAE; JEONG HUI RAK 权利人:LG CHEMICAL LTD 摘要:The present invention relates to a novel preparation method that can be advantageously utilized for the synthesis of a xanthine oxidase inhibitor of Chemical Formula 1.
专利号:US-2024262809-A1 优先权日:2021-04-27 标题:Method for preparing intermediate for synthesis of xanthine oxidase inhibitor
1: Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. Am J Kidney Dis. 2015 Dec;66(6):945-50. doi: 10.1053/j.ajkd.2015.05.017. Epub 2015 Jul 30. doi: 10.1007/s10157-015-1095-1. Epub 2015 Feb 13. doi: 10.5414/CP202394. doi: 10.1111/hdi.12313. Epub 2015 May 21. doi: 10.1371/journal.pone.0150661. eCollection 2016. 6: Tani S, Nagao K, Hirayama A. Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study. Clin Drug Investig. 2015 Dec;35(12):823-31. doi: 10.1007/s40261-015-0349-8. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. doi: 10.1093/annonc/mdv317. Epub 2015 Jul 27. doi: 10.1016/j.jpba.2015.05.020. Epub 2015 Jun 11. doi: 10.1016/j.jjcc.2014.12.017. Epub 2015 Jan 31. doi: 10.1097/RHU.0000000000000322. 11: Yamamoto T, Hidaka Y, Inaba M, Ishimura E, Ooyama H, Kakuta H, Moriwaki Y, Higami K, Ohtawara A, Hosoya T, Nishikawa H, Taniguchi A, Ueda T, Yamauchi T, Fujimori S, Mineo I, Yamanaka H. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients. Mod Rheumatol. 2015 Sep;25(5):779-83. doi: 10.3109/14397595.2015.1016257. Epub 2015 Jun 12. doi: 10.1097/MBC.0000000000000335.
合成参考文献
参考文献:10.1107/s1600536811014905 摘要:Jiang QY, Qian JJ, Gu JM, Tang GP, Hu XR. Febuxostat methanol solvate. Acta Crystallogr Sect E Struct Rep Online. 2011 May 01;67(Pt 5):o1232. 参考文献:10.2215/cjn.00320111 摘要:Goldfarb DS. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. Clin J Am Soc Nephrol. 2011 Aug;6(8):2093–7.